Alzheimer’s disease (AD) is a serious public health crisis with only one current modifying treatment. The reduction of amyloid load by targeting γ-secretase (GS) has been a leading approach in AD drug discovery and development. Despite the focus on GS inhibition, multiple GS inhibitors (GSIs) have failed in clinical trials as a result of side effects including exacerbated cognitive decline. These side effects are largely attributable to inhibition of normal GS function. Standard enzyme inhibitors target catalytic or allosteric sites of the enzyme, including the active site presenilin, as previous GSIs did. To avoid issues observed from broad-spectrum GSIs we discovered that fragment 6H8 that covalently binds to the substrate of GS, the transmembrane domain of amyloid precursor protein (APPTM). Nuclear Magnetic Resonance (NMR) Spectroscopy combined with MALDI-TOF-MS established 6H8 covalently binds to APPTM. 6H8 acts as a Michael acceptor and covalently links to the side chain amines of lysine residues, specifically targeting a cluster of C-terminal lysines K53–K55. Through this modification, 6H8 can inhibit intramembrane proteolysis of an archaeal homolog of presenilin (the active subunit of GS) via substrate binding with a 2–4 μM IC50, determined by a gel-based cleavage assay. 6H8, while too small to be an effective drug candidate, can be combined with a specific non-covalent partner and function as an effective covalent warhead of a targeted covalent inhibitor (TCI). The future development of the 6H8 fragment into the covalent warhead of a TCI is, to our knowledge, a novel approach to AD drug discovery.

KEYWORDS
Alzheimer’s disease (AD), targeted covalent inhibitor, covalent warhead, amyloid precursor protein (APP), intramembrane proteolysis

Introduction

Alzheimer’s Disease (AD) is a neurological disease currently affecting close to six million Americans, projected to rise dramatically over the next 10 years (Cummings and Cotman, 1995; Alzheimer’s Association, 2022). AD is the sixth leading cause of death overall and the fifth for people over the age of 65. With our rapidly aging population, a cure for AD remains at the forefront of the unmet medical needs of this nation (Cummings and Cotman, 1995; Alzheimer’s Association, 2022). A major neuropathological hallmark of AD is the presence of senile plaques in the cerebral
cortex and hippocampus (Price et al., 1998). Senile plaques, also called amyloid plaques, are mainly composed of extracellular aggregates of amyloid \( \beta \)-peptides (A\( \beta \)s); and it has been hypothesized that these plaques initiate a pathological cascade resulting in cognitive decline (Selkoe, 2001; Selkoe and Hardy, 2016).

\( \gamma \)-secretase (GS) has four essential proteins subunits, presenilin (PS), nicastrin (Nct), anterior pharynx-defective 1 (Aph-1), and presenilin enhancer 2 (Pen-2), (Esler et al., 2000; Li Y. et al., 2000; Li Y. M. et al., 2000; De Strooper, 2003; Wolfe and Kopan, 2004; Wolfe, 2006; Ahn et al., 2010) where PS is the catalytic subunit (Jarrett et al., 1993; Francis et al., 2002; Haapasalo and Kovacs, 2011; Coric et al., 2012). GS is an intramembrane-cleaving protease (I-CLiP) that hydrolyses peptide bonds located inside the membrane lipid bilayer allowing for the release of bioactive peptide fragments (Haze et al., 1999; Niwa et al., 1999; Brown et al., 2000; Lal and Caplan, 2011; Lichtenhaller et al., 2011). I-CLiPs are critical for a myriad of biological processes and therefore are implicated in a number of disease pathologies like AD (Winter-Vann and Casey, 2005; Lichtenhaller et al., 2011; Düsterhöft et al., 2017). While there are multiple classifications of I-CLiPs, GS (and subsequently PS) is a di-aspartyl protease which is characterized by two catalytic aspartates. One catalytic aspartate is adjoining by a GXGD motif where G is glycine, X is any amino acid, and D is aspartate (Steiner et al., 2000; Fluhrer et al., 2009). GS cleaves APP’s transmembrane domain, in addition to over 90 other physiological substrates including Notch (Francis et al., 2002; Haass and Steiner, 2002; Haapasalo and Kovacs, 2011). As a result, inhibiting GS may result in major disruptions of homeostatic functions, such as cell adhesion and signaling.

A\( \beta \), the major component of senile plaques, is generated from amyloid precursor protein (APP). APP is cleaved consecutively by two proteases: \( \beta \)- and \( \gamma \)-secretase (Figure 1) (Jarrett et al., 1993). \( \beta \)-secretase cleaves APP and generates a C-terminal 99 residue construct (C99). GS then cleaves C99 in the transmembrane domain (APPTM) which releases A\( \beta \) into the extracellular or luminal space (Jarrett et al., 1993). A\( \beta \) has two major isoforms: A\( \beta \)40 and A\( \beta \)42, composed of 40 and 42 residues, respectively. A\( \beta \)40 is benign in comparison to A\( \beta \)42, which has a much higher propensity to aggregate into neurotoxic oligomers and fibrils.

Despite the focus on A\( \beta \) as a potential drug target for AD, all but one (aducanumab) anti-A\( \beta \) drug failed in clinical trials (Coric et al., 2012; Doody et al., 2013; Coric et al., 2015; Ferrero et al., 2016; Abyadeh et al., 2021). Two broad-spectrum GS inhibitors (GSIs), avagacestat and semagacestat, failed due to worsening cognition in patients in addition to other serious adverse effects (Coric et al., 2012; Doody et al., 2013; Coric et al., 2015). As of now, the only FDA-approved anti-A\( \beta \) treatment is aducanumab, which is not without controversy. The basis of the controversy is insufficient data demonstrating the efficacy of the drug in improving the cognitive function of AD patients (Ferrero et al., 2016; Abyadeh et al., 2021). Despite the failure of GSIs in clinical trials and the aducanumab controversy, there is compelling evidence that A\( \beta \) is a causative agent in AD, including human genetics of familial AD (FAD) (Selkoe, 2001; De Jonghe et al., 2002; Chen et al., 2014) and Down’s syndrome, (Lejeune et al., 1959; Head et al., 2012), A\( \beta \) toxicity and related neuron inflammation, (Eng et al., 2004; Shankar et al., 2008), and potentiation of tau pathology (Jin et al., 2011).
increased Aβ42/Aβ40 ratio which contributes to the early onset of AD. To better characterize AD and FAD, our lab has previously solved the structure of APPTM, the substrate of GS for Aβ generation, via solution NMR in micelles (Chen et al., 2014). We also studied FAD mutations (V44M and V44A) within APPTM and found that these mutations likely enhance the flexibility and therefore the accessibility of the initial ε-cleavage site for the Aβ42 production line, contributing to the higher Aβ42/Aβ40 ratio seen in FAD (Fluhrer et al., 2009). Our lab also demonstrated that the C-terminal lysine cluster of APPTM (K53-K55) participates in the initial docking of APPTM to intramembrane protease GS, coupled with helical unwinding to ready the substrate for peptide bond hydrolysis (Clemente et al., 2018). Recently, the cryo-EM structure of GS complexed with APP substrate revealed an α-helical to β-strand transition at the C-terminus of APPTM. This transition exposes the initial ε-cleavage sites to interact with the active site of γ-secretase (Zhou et al., 2019).

The large number of endogenous substrates of GS presents a significant obstacle to the development of GSIs, exemplified by the aforementioned clinical trial failures (Haapasalo and Kovacs, 2011). These trials were ultimately discontinued due to serious side effects, attributed to the suppression of γ-secretase activity with other endogenous substrates such as tyrosinase, Notch, and N-cadherin (De Jonghe et al., 2002; Marambaud et al., 2003; Crump et al., 2012; Doody et al., 2013). Additionally, GSIs that bind the catalytic subunit of GS (PS) pose a particular issue; PS is involved in learning, memory, and neuronal survival, which may have contributed to the exacerbated cognitive decline observed in clinical trials (Saura et al., 2004; Wines-Samuelson et al., 2010; Haapasalo and Kovacs, 2011; Watanabe et al., 2012; Barthet et al., 2013). Considering that APPTM is the substrate for GS that generates Aβ, an alternative approach previously explored by the Wang lab is to target the substrate (APPTM) to reduce the production of Aβ (Zhao et al., 2020). A substrate-specific inhibitor is not anticipated to affect GS complex formation, presenilin function, and most importantly normal function of GS with other endogenous substrates, thereby reducing the potential side effects of broad GSIs.

The main consideration for making APPTM the target of drug discovery is that transmembrane helices, like APPTM, are difficult drug targets, due to the lack of binding pockets. This issue can be mitigated with the implementation of a covalent modifying drug compound that does not require a specific binding pocket to dock while also benefiting from the zero off rate. We report a novel compound, 6H8, which covalently modifies APPTM at three adjacent lysines in the C-terminal juxtamembrane. With only one disease-modifying therapy approved by the FDA, 6H8 serves as a covalent warhead poised to be used in rational drug discovery that spares the activity of GS and as a novel drug discovery avenue (Ferrero et al., 2016; Abyadeh et al., 2021).

Results

6H8 binds the C-terminus of transmembrane domain of amyloid precursor protein as shown by 2D NMR

Initial NMR screening of a fragment library (Maybridge Ro3 1000 library) using APPTM as the target yielded 6H8 as a binder of APPTM. We then explored the binding interaction using 2D 1H-15N transverse relaxation optimized spectroscopy (TROSY) (Figure 3A), which correlates the proton and nitrogen of the amide group of each individual residue in the sequence of APPTM (Figure 2). To have the optimal line width of APPTM in dodecyl phosphocholine (DPC) micelles, we used a TROSY sequence for the 2D NMR experiments, which yields a fingerprint-like spectrum that can be used to identify and monitor changes in the protein. Binding events and changes to the local chemical environment of the protein can be observed with a selective line broadening indicated by peak height reduction into the baseline at or near that residues’ side.

Overall, 6H8 had a considerable reduction in signal at and near Lys residues. Figures 3A,C highlight specific residues of APPTM impacted by the 10-M excess of 6H8 after 3.5 h of incubation at 37°C. Peaks that experience height reduction, indicated by an I/I₀ value under 0.5, where over half the initial signal is lost, undergo the greatest chemical change with the addition of 6H8. Peaks with the lowest I/I₀ values were at the C-terminal lysine residues K53, K54, and K55 (I/I₀ values: 0.40, 0.25, and 0.42 respectively) and their neighbors M51, L52, L56, and E57 (I/I₀ values: 0.36, 0.32, 0.41, and 0.22 respectively). In analyzing these values and overall spectra, we observe the binding interaction between 6H8 and APPTM specifically targets the C-terminal lysine cluster given the reactivity of the free amine groups at the end of lysine sidechains. With clear interaction between 6H8 and APPTM confirmed by 2D TROSY NMR, we wanted to further explore if 6H8 could inhibit the intramembrane proteolysis of APPTM in the amyloidogenic cascade (Figure 1).

6H8 inhibits cleavage by presenilin homologue MAMRE50

To determine if 6H8 could inhibit APPTM cleavage by PSH, an in vitro gel-based cleavage assay was employed using an archaeal homolog of presenilin (PSH) MAMRE50. This homolog replicates most structural and biochemical features of presenilin/GS, serving as a substitute for fully formed GS, which is difficult to overexpress and purify (De Strooper et al., 2021).
Li Y. M. et al., 2000; Selkoe and Wolfe, 2007; Li et al., 2012; Dang et al., 2015; Zhao et al., 2020). APPTM was incubated with PSH for 24 h at 37°C to obtain full cleavage of APPTM under these conditions. The extent of cleavage was monitored by the intensity of the lower molecular weight band that appears slightly below the fully intact APPTM, indicating successful intermembrane proteolysis of APPTM by PSH (Figure 4) (Li et al., 2012; Dang et al., 2015).

Control samples were run with every gel for both positive and negative hits. Our negative control is a sample containing only APPTM and PSH allowing for full uninhibited cleavage; whereas our positive control utilizes a known PSH inhibitor at 31°C to represent fully inhibited cleavage (Zhao et al., 2006). 6H8-modified APPTM was further incubated with PSH at 37°C. The extent of cleavage was determined via SDS-PAGE gel electrophoresis. Initial screening of 6H8 in this assay was done from 0.2 to 20 μM. IC₅₀ was under 10 μM. Secondary assay with a smaller range of 6H8 (1–10 μM) was performed; the IC₅₀ was between 2 and 4 μM.
6H8 range was between 1 and 10 μM, with complete inhibition observed between 2 and 4 μM. Given the low, micromolar IC50, further experiments were conducted with 6H8 for future drug development.

**6H8 covalently modifies transmembrane domain of amyloid precursor protein**

MALDI-TOF-MS was utilized to further characterize the binding interactions between 6H8 and APPTM. NMR can illuminate many things about the binding interactions, but it lacks the ability to distinguish between covalent and non-covalent interactions. Covalent modification is advantageous for drug targets like APPTM due to its lack of binding pocket as a helical dimer. Incubation of APPTM in the presence of 5 M excess of 6H8 shows complete conversion of the APO protein to covalently modified APPTM with up to six additions of 6H8 (Figure 5). With multiple Lys in the sequence (Figure 3B), there are ample positions for multiple additions of 6H8 observed in the MALDI-TOF spectrum (Figure 5). Differences in the original mass of the APO peak (5,590 m/z) correspond to the molecular weight of 6H8 (176 Da) missing lacking a hydrogen (\(\Delta m = 175\)) being added to APPTM. Molecular weight changes corresponding to multiple additions can be seen in Figure 5, with a maximum of six additions, shifting the APO protein mass by 1,050 m/z. Confirmation of covalent modification provides valuable information when determining the structure-activity relationships as we know there must be covalently binding moiety present under given oxidizing conditions.

**Reducing conditions eliminate 6H8 binding to transmembrane domain of amyloid precursor protein and allows for complete cleavage by presenilin homologue**

In standard reaction/oxidizing conditions (25 mM Na2PO4, 4% DPC, pH 7.2), 6H8 readily binds to APPTM. Given that the hydroquinone moiety is known to readily oxidize into quinone, and the time-dependent color change of 6H8 stocks in an aqueous buffer (from colorless to yellow-brown), we hypothesized that oxidation causes 6H8 to act as a pro-drug-like molecule (Radel et al., 1982; Yadav et al., 2008). The quinone conversion reveals the required α, β unsaturated ketone for a Michael addition with the free amines of Lys side chains and the N-terminus.

To test this hypothesis, we introduced the reducing agent tris(2-carboxyethyl) phosphine (TCEP) to prevent the conversion of 6H8 from inactive hydroquinone to active quinone form. Initial testing of this hypothesis was done using the PSH cleavage assay. An excess of 6H8 (0.6 and 0.8 mM) was incubated with APPTM and PSH both with and without 1 mM of TCEP (Figure 6A, red and black respectively). Given that the IC50 of 6H8 was between 2 and 4 μM as determined by this PSH assay, this assay was done with an extreme excess of 6H8. Under normal oxidizing conditions, both 0.6 and 0.8 mM 6H8 completely inhibit PSH cleavage of APPTM as no cleavage product is present. In contrast, the lanes with the same excess amounts of 6H8 incubated with 1 mM of reducing agent TCEP demonstrate complete cleavage of APPTM (Figure 6). These results confirm our hypothesis that 6H8 needs to be in an oxidizing environment to inhibit cleavage by PSH and by extension GS.

**6H8 binding to the C-terminus of transmembrane domain of amyloid precursor protein is diminished in reducing conditions as shown by 2D NMR**

As a follow-up to the PSH inhibition assay, a 2D NMR TROSY experiment was performed to determine if a reducing agent can inhibit binding to APPTM in its entirety. Figure 6B exemplifies a 2D NMR TROSY under the same conditions as the TROSY depicted in Figure 3A (25 mM Na2PO4, 4% DPC, 90% H2O/10% D2O) save for the presence of ten-fold molar excess of TCEP in relation to 6H8. In the presence of TCEP, there is no binding between 6H8 and APPTM, as demonstrated by the near-identical spectra between apo APPTM...
and APPTM with 6H8 in reducing conditions (APPTM 50 μM; TCEP 5000 μM; 500 μM 6H8). We provide a comparison with an APPTM incubated with 10-fold molar 6H8 in oxidizing conditions to demonstrate the significant difference with active APPTM-6H8 binding (1:10 APPTM: 6H8; Figure 6B, right-most spectrum). These results affirm that the oxidizing environment is essential for the covalent linkage between 6H8 and APPTM.

6H8 covalently binds transmembrane domain of amyloid precursor protein under oxidizing conditions via a michael addition mechanism

We propose that the reaction between 6H8 and APPTM follows a water-catalyzed Michael addition similar to that reported by Yadav et al. (2008). The first step involves oxidation of the hydroquinone moiety of 6H8 to a quinone structure with water as the catalyst. This quinone structure provides a, β unsaturated ketone (Michael acceptor) for Michael addition. The amine group at the end of lysine side chains K53-K55 (Michael donor) performs a nucleophilic attack on the unsaturated ketone, followed by solvent-driven proton abstraction and reestablishment of resonance (Figure 7). Water is the most likely catalyst in our system as an aqueous buffer (25 mM Na2PO4, 4% DPC, pH 7.2). Figure 7 illustrates the mechanism described above using water as the catalyst for the reaction at near-neutral pH (pH 7.2).

Discussion

Developing disease-modifying strategies against AD is crucial as the US population ages in the coming decades. Combating senile plaque formation is a potential drug target to slow down the progression of AD. Senile plaques are composed of aggregated Aβ
which are generated during the intermembrane proteolysis of APPTM in C99 (Barthet et al., 2013). Therefore, targeting the C99/γ-secretase interface is a legitimate approach to reducing Aβ generation and overall amyloid load. Previous clinical trials targeting the amyloidogenic pathway-focused efforts on inhibition of γ-secretase (GS), however, these trials were discontinued due to acute side effects and accelerated cognitive decline. Serious side effects likely stemmed from inhibition of cleavage of the 90 other known physiological substrates of GS. The inhibition of presenilin likely resulted in the worsening cognition because of its established role in neuronal survival, learning, and memory retention (Saura et al., 2004; Wines-Samuelson et al., 2010; Crump et al., 2012; Watanabe et al., 2012). To avoid the pitfalls of previous trials, we focused our efforts on compounds that target the amyloid substrate of GS. This approach would allow GS to maintain normal function for other substrates as well as avoid inhibiting the critical functions of presenilin.

Utilizing NMR, MS, and enzyme cleavage assays, we report the discovery of a novel fragment named 6H8 that covalently binds APPTM and inhibits cleavage of PSH, a homolog of the catalytic subunit of GS. The discovery of this compound follows our discovery of a similar compound C1 that was the first reported covalent GS inhibitor (Barthet et al., 2013). The binding interaction of 6H8 to APPTM is similar to C1 in both mechanism and site of binding, undergoing Michael additions with the free amines at K28 and K53-55 (Takami et al., 2009).

NMR titration showed a significant interaction of 6H8 to the C-terminal juxtamembrane region of APPTM (Figure 3A) targeting specifically the juxtamembrane triple Lys cluster K53-K55. APPTM is shown to have an MW increase by MALDI-TOF-MS, which indicates that 6H8 covalently binds to APPTM. Combining the results of NMR and MALDI-TOF-MS, it is apparent that 6H8 covalently modifies at the C-terminal Lys cluster of APPTM. This location of covalent modification is advantageous as it is near the initial ε-cleavage sites of presenilin, T48, and I49 (Takami et al., 2009). Through mutagenesis, the juxtamembrane residues of APPTM have been shown to play an important role in GS cleavage (Kukar et al., 2011; Li et al., 2017; Yan et al., 2017). Our previous NMR studies established that the C-terminal lysine cluster of APPTM undergoes the largest CSPs upon initial docking of PSH, revealing their importance during intramembrane proteolysis (Clemente et al., 2018). Upon docking to PSH, APPTM exhibits a pattern of reduced chemical shifts of amide protons at the C-terminal half of APPTM indicating weakened helical hydrogen bonds, due to the unwinding of the α-helical geometry (Clemente et al., 2018). These studies reinforce the C-terminal region of APPTM as a promising drug target for novel drug discovery targeting inhibition of APP by GS.

In our gel-based cleavage assay using PSH, 6H8 modified APPTM significantly inhibited cleavage of APPTM/APP by PSH with an IC50 range between 2 and 4 μM (Figure 4). Inhibition of GS cleavage of 6H8 modified APPTM can be rationalized by the cryo-EM structure of the APP C83/GS complex. In this complex APPTM takes on an extended β conformation that exposes the ε-cleavage sites by forming a β-sheet with two β-strands from PS (Marambaud et al., 2003). 6H8’s modification of APPTM at the C-terminal Lys (K53-55) likely interferes with the α to β transition and/or formation of the β-sheet complex between APP and presenilin, thus inhibiting cleavage by presenilin and ultimately GS.

One major concern with covalent modifying drugs is the potential for off-target reactivity and promiscuous binding. While conventionally the pharmaceutical industry avoids covalently modifying drugs, many first-in-class drugs like aspirin and penicillin covalently modify their targets and encompass roughly 30% of the current drug market (Roth et al., 1975; Wright et al., 2014). Despite the traditional hesitation toward covalent drugs, there are considerable benefits to these drugs, such as a zero-off rate and high efficacy. Both factors facilitate lower concentration and less frequent dosing, which assists in mitigating off-target and side effects while dramatically increasing patient compliance (Bauer, 2015). There has been a surge in covalent drug candidates in development specifically targeting “undruggable” targets, like APPTM, that have no obvious binding pocket. While 6H8 is a small fragment that is potentially promiscuous, we plan to design a targeted covalent inhibitor (TCI) using 6H8 that combines the benefits of covalent and non-covalent inhibitors (Singh et al., 2011). Our plans for TCI development include using 6H8s as the covalent warhead attached to a non-covalent binding linker.

Inhibition of the active subunit of GS (presenilin) limits the production of Aβ and overall senile plaque load in the AD brain. Here we report the discovery of 6H8 a fragment that covalently modifies APPTM to inhibit cleavage by PSH and by extension GS. This study serves as a follow-up to our lab’s initial discovery of novel covalent modifier C1, in which we demonstrated that targeting the substrate of GS alone can sufficiently reduce Aβ production (Barthet et al., 2013). This method of targeting the substrate of GS, APPTM, continues this new direction in AD discovery targeting amyloid load as the disease-modifying strategy. This methodology can readily be applied to other “non-druggable” targets where there is a vested interest in maintaining the normal function of the enzyme that cleaves other physiological substrates.

**Summary/conclusion**

**Targeting the substrate of GS (APP) allows for normal function of GS while reducing the generation of amyloid plaques**

One major pathogenic hallmark of AD is the formation of senile plaques (Price et al., 1998). These plaques are formed via intramembrane membrane proteolysis of APP by GS. Given its role in plaque formation, GS inhibition has been a traditional target for AD drug discovery, with limited success. The 90+ endogenous substrates of GS, and two notable failures of
Covalent fragments can serve as a reactive covalent warhead in rational drug design of targeted covalent inhibitors

While a covalently modifying fragment is not ready for implementation as a drug lead given a high probability of binding promiscuity, we propose can serve as a covalent warhead for TCI development. TCIs offer the specificity of a non-covalent binder with the zero off rate of a covalent inhibitor. (Singh et al., 2011; Wright et al., 2014; Bauer, 2015). Based on NMR titration data, 6H8 binds to the transmembrane region of APPTM and inhibits cleavage by PSH, and is readily available for addition to a non-covalent binder of APPTM.

Materials and methods

Transmembrane domain of amyloid precursor protein overexpression and purification

The fusion constructs maltose-binding protein APPTM (MBP-APPTM) was transformed into Bl21DE3 Codon Plus RILp cells. Colonies with ampicillin resistance were inoculated into a 200 ml LB culture and grown O/N at 37°C. The culture was spun down, washed to remove lingering LB, and transferred to 15N labeled minimal media (1M MgSO4, 1M CaCl2, 20% (w/v) glucose, 1g/L15NH4Cl). The culture was grown at 37°C until an OD600 of ~0.6, then induced with 2 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). Cultures were allowed to overexpress at 16°C for 27 h, harvested by centrifugation, and stored in −80°C until lysis.

Cells were resuspended in aqueous buffer (20 mM Tris, 500 mM NaCl, 20 mM Imidazole, 0.5 mM PMSF) for lysis via microfluidizer at 80 psi. Insoluble cell debris was pelleted by centrifugation (10,000 × g, 4°C), and membranes were harvested from the resulting supernatant by ultra-centrifugation using a Beckman Proteomelab XL-I ultracentrifuge (Ti45 fixed angle rotor, 40,000 rpm, 16–20 h).

Membrane pellets were manually homogenized in a 55 ml tissue grinding chamber with a smooth pestle (Wheaton 358054) using 30 ml solubilization buffer (20 mM Tris, 500 mM NaCl, 20 mM Imidazole, and 2% w/v n-dodecylphosphocholine). The membrane mixture was passed through two 5 ml Ni-NTA columns to purify His-tagged MBP-APPTM. Ni-NTA columns were equilibrated with 50 ml of H2O and 50 ml of HisTrap Buffer A (20 mM Tris, 500 mM NaCl, 20 mM Imidazole, and 0.1% w/v DPC). Solubilized membranes were loaded onto the column, washed with 100 ml HisTrap A until A280 ~0, and eluted with an isocratic elution of TCEP (1 mM for NMR studies, and 1 mM for PSH assays).

Before cleavage by thrombin, the protein was dialyzed into thrombin digest buffer (10 mM Na2HPO4, 140 mM NaCl, 3 mM β-mercaptoethanol, 0.05% w/v DPC). MBP-APPTM was digested by 10 U of thrombin/mg of fusion protein at room temperature for 48 h. Post cleavage, APPTM was separated from the cleaved tag using
Ni-NTA following the same steps as previously described. APPTM was dialyzed into NMR buffer (25 mM Na₂PO₄ pH 7.2) and concentrated up to 4% DPC. Protein concentration determined by BCA assay.

**NMR-based fragment library screening**

Using APPTM as the target fragments of compounds from the Maybridge Ro3 1000 library (under 200 Da) were screened via NMR spectroscopy. Positive hits were marked by significant chemical shift perturbations (CSPs) and/or selective line broadening on a 1H-15N 2D transverse relaxation optimized spectroscopy (TROSY) NMR spectrum of APPTM. Negative hits result in a TROSY spectrum identical to the APO APPTM spectrum. Multiple positive hits were obtained using this screening technique, including C1, the covalent modifer of APPTM which we previously published (Barthet et al., 2013). The library was screened by pooling ten compounds and incubating them with APPTM at 318 K. Samples that yielded positive results were parsed by individually incubating the compounds with APPTM allowing for the identification of individual positive hit compounds.

**Gel-based cleavage assay by presenilin homologue MAMRE50 was used to determine efficacy inhibiting intramembrane proteolysis**

A gel-based assay previously established in this lab to monitor the cleavage of APPTM and 6H8 modified APPTM by presenilin homolog MAMRE50 (PSH) was utilized (Zhao et al., 2020). APPTM (5 µM) was incubated with varying concentrations of 6H8. Native APPTM and 6H8-modified APPTM were incubated with PSH (20 µM, 37°C, 24 h) before running on a 12% SDS-PAGE gel (200 V for 35 min). III-31-C, a known γ-secretase inhibitor, was pre-incubated with PSH for 1 h before adding the substrate serves as a positive control for complete inhibition. Initial IC₅₀ PSH assay utilized a range of concentrations of 6H8 from 0.2 to 20 µM (0.2, 0.4, 0.6, 0.8, 1, 5, 10, 15, and 20 µM) (Figure 4A). Following initial PSH assay another assay was performed using a smaller range to narrower the IC₅₀ range (1, 2, 4, 6, 8, and 10 µM).

**Solution NMR**

Original 15N-1H TROSY spectra of APPTM via solution NMR has already been accomplished and reported in the BMRB (Entry 18649) (Zhao et al., 2020). A well-resolved 1H-15N TROSY spectra were recorded in 10% D₂O on an 800 MHz Bruker Advance II spectrometer equipped with cryogenic probes. Titrations of APPTM with 6H8 were monitored for both chemical shift perturbations (CSPs) and selective line broadening. CSPs are indicated by a linear shift and are indicative of fast exchange in the system, whereas selective line broadening corresponds to intermediate exchange in the system leading to a decrease in peak height of affected residues. 6H8 was added to a 15N-labeled APPTM sample at a ratio of 1:10. 1H-15N TROSY spectra were collected for APPTM before and after adding 6H8 at 318K. Spectra were analyzed using Sparky. (Lee et al., 2015).

**MALDI-TOF-MS**

MALDI-TOF-MS was applied for the detection of 6H8 covalent modification of APPTM. All reactions were performed using 15N labeled APPTM in NMR buffer. Detergent in all samples was removed (Pierce™ Detergent Removal Spin Columns 87777) for better detection. MALDI-TOF-MS spectra of APPTM were acquired on a Bruker Daltonics-autoflex™ speed MALDI-TOF/TOF spectrometer. A linear mode was applied for detecting APPTM with sinapinic acid as the matrix. MALDI-TOF-MS spectra of APPTM (5,590 Da, 50 µΜ) were acquired with a 1:5 ratio of 6H8 treatment after 16 h incubation at 37°C.

**Data availability statement**

The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.

**Author contributions**

AE designed and executed the MALDI-TOF-MS, MALDI, and PSH assay experiments, analyzed the data, and wrote the original manuscript. JZ carried out initial NMR screening of drug candidates with APPTM. YX overexpressed and purified APPTM and PSH. JG provided guidance for NMR experiments. CW designed the research and supervised the project.

**Funding**

This work was supported by a grant from Warren Alpert Foundation (to CW), NIH grant R21-NS109926 (to CW), and NIH grant R35-GM127040 (to YX).

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Steiner, H., Kostka, M., Romig, H., Basset, G., Pesold, B., Hardy, J., et al. (2000). Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases. Nat. Cell Biol. 2 (11), 848–851. doi:10.1038/35041097

Takami, M., Nagashima, Y., Sano, Y., Ishihara, S., Morishima-Kawashima, M., Funamoto, S., et al. (2009). gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J. Neurosci. 29 (41), 13942–13952. doi:10.1523/NEUROSCI.2362-09.2009

Watanabe, H., Xia, D., Kajiwara, T., Kelleher, R. J., and Shen, J. (2012). Familial frontotemporal dementia-associated presenilin-1 c.548G>T mutation causes decreased MRNA expression and reduced presenilin function in knock-in mice. J. Neurosci. 32 (15), 5085–5096. doi:10.1523/NEUROSCI.0317-12.2012

Wines-Samuelson, M., Schulte, E. C., Smith, M. J., Aoki, C., Liu, X., Kelleher, R. J., et al. (2010). Characterization of age-dependent and progressive cortical neuronal degeneration in presenilin conditional mutant mice. PLoS One 5 (4), e10195. doi:10.1371/journal.pone.0010195

Winter-Vann, A. M., and Casey, P. J. (2005). Post-prenylation-processing enzymes as new targets in oncogenesis. Nat. Rev. Cancer 5 (3), 405–412. doi:10.1038/nrc1612

Wolfle, M. S., and Kopan, R. (2004). Intramembrane proteolysis theme and variations. Science 305 (5687), 1119–1123. doi:10.1126/science.1096817

Wolfle, M. S. (2006). The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry 45 (26), 7931–7939. doi:10.1021/bi060799c

Wright, P. M., Seiple, J. B., and Myers, A. G. (2014). The evolving role of chemical synthesis in antibacterial drug discovery. Angew. Chem. Int. Ed. Engl. 53 (34), 8840–8869. doi:10.1002/anie.201310843

Yadav, J. S., Reddy, B. V., Swaney, T., and Shankar, K. S. (2008). Green protocol for conjugate addition of amines to p-quinones accelerated by water. Monatsh. Chem. 139 (11), 1317–1320. doi:10.1007/s00706-008-0971-9

Yan, Y., Xu, T. H., Helmer, K., and Xu, H. E. (2017). Defining the minimum substrate and charge recognition model of gamma-secretase. Acta Pharmacol. Sin. 38 (10), 1412–1424. doi:10.1038/aps.2017.35

Zhao, G., Tan, J., Mao, G., Cui, M.-Z., and Xu, X. (2006). The same gamma-secretase accounts for the multiple intramembrane cleavages of APP. J. Neurochem. 100 (3), 1234–1246. doi:10.1111/j.1471-4159.2006.04302.x

Zhao, J., Xian, Y., Liu, X., Kim, S., Wu, X., Barros, M., et al. (2020). Substrate interaction inhibits γ-secretase production of amyloid β peptides. Chem. Commun. 56 (17), 2578–2581. doi:10.1039/c9cc09170b

Zhou, R., Yang, G., Guo, X., Zhou, Q., Lei, J., and Shi, Y. (2019). Recognition of the amyloid precursor protein by human γ-secretase. Science 363 (6428), eaaw0930. doi:10.1126/science.aaw0930